These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33367372)

  • 21. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
    Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ
    J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
    Tai YT; Cho SF; Anderson KC
    Front Immunol; 2018; 9():1822. PubMed ID: 30147691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1/PD-1 signal deficiency promotes allogeneic immune responses and accelerates heart allograft rejection.
    Wang W; Carper K; Malone F; Latchman Y; Perkins J; Fu Y; Reyes J; Li W
    Transplantation; 2008 Sep; 86(6):836-44. PubMed ID: 18813109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts.
    Hori J; Wang M; Miyashita M; Tanemoto K; Takahashi H; Takemori T; Okumura K; Yagita H; Azuma M
    J Immunol; 2006 Nov; 177(9):5928-35. PubMed ID: 17056517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality.
    Saha A; O'Connor RS; Thangavelu G; Lovitch SB; Dandamudi DB; Wilson CB; Vincent BG; Tkachev V; Pawlicki JM; Furlan SN; Kean LS; Aoyama K; Taylor PA; Panoskaltsis-Mortari A; Foncea R; Ranganathan P; Devine SM; Burrill JS; Guo L; Sacristan C; Snyder NW; Blair IA; Milone MC; Dustin ML; Riley JL; Bernlohr DA; Murphy WJ; Fife BT; Munn DH; Miller JS; Serody JS; Freeman GJ; Sharpe AH; Turka LA; Blazar BR
    J Clin Invest; 2016 Jul; 126(7):2642-60. PubMed ID: 27294527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers.
    Moore EC; Cash HA; Caruso AM; Uppaluri R; Hodge JW; Van Waes C; Allen CT
    Cancer Immunol Res; 2016 Jul; 4(7):611-20. PubMed ID: 27076449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone marrow mesenchymal stromal cells attenuate liver allograft rejection may via upregulation PD-L1 expression through downregulation of miR-17-5p.
    Chen Q; Zhou R; Zhang Y; Zhu S; Xiao C; Gong J; Li K; Tang H; Sun C; Zhang J
    Transpl Immunol; 2018 Dec; 51():21-29. PubMed ID: 30092337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD-1/PD-L1 costimulatory pathway-induced mouse islet transplantation immune tolerance.
    Li T; Ma R; Zhu JY; Wang FS; Huang L; Leng XS
    Transplant Proc; 2015; 47(1):165-70. PubMed ID: 25645798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Engineering Cell Membrane-Based Nanovesicles for Melanoma Tumor Treatment.
    Xin S; Wu Y; Huang Z; Huang Y; Jia B; Zhao J
    J Biomed Nanotechnol; 2021 May; 17(5):838-845. PubMed ID: 34082870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy.
    Zhang X; Wang C; Wang J; Hu Q; Langworthy B; Ye Y; Sun W; Lin J; Wang T; Fine J; Cheng H; Dotti G; Huang P; Gu Z
    Adv Mater; 2018 May; 30(22):e1707112. PubMed ID: 29656492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blockade of the OX40/OX40L pathway and induction of PD-L1 synergistically protects mouse islet allografts from rejection.
    Li T; Ma R; Zhu J; Wang F; Huang L; Leng X
    Chin Med J (Engl); 2014; 127(14):2686-92. PubMed ID: 25043090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Engineering high-affinity dual targeting cellular nanovesicles for optimised cancer immunotherapy.
    Zhang L; Zhao X; Niu Y; Ma X; Yuan W; Ma J
    J Extracell Vesicles; 2023 Nov; 12(11):e12379. PubMed ID: 37974395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
    Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T cell checkpoint regulators in the heart.
    Grabie N; Lichtman AH; Padera R
    Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1.
    Patera AC; Drewry AM; Chang K; Beiter ER; Osborne D; Hotchkiss RS
    J Leukoc Biol; 2016 Dec; 100(6):1239-1254. PubMed ID: 27671246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of programmed death ligand 1 in dendritic cells inhibits allogeneic lymphocyte activation in mice.
    Li W; Wang X; Chen R; Zhu H; Chen G; Sun X
    J Surg Res; 2012 Aug; 176(2):e79-87. PubMed ID: 22381170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Engineering PD-L1 Cellular Nanovesicles Encapsulating Epidermal Growth Factor for Deep Second-Degree Scald Treatment.
    Zhu XF; Su DD; Tian XH; Yang C; Zhang WX; Yang XR; Zhang MQ; Xi LF; Wei L; Chen HB; Cheng F; Pang YX
    J Biomed Nanotechnol; 2022 Mar; 18(3):898-908. PubMed ID: 35715909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Programmed Death Ligand 1 Plays a Neuroprotective Role in Experimental Autoimmune Neuritis by Controlling Peripheral Nervous System Inflammation of Rats.
    Ding Y; Han R; Jiang W; Xiao J; Liu H; Chen X; Li X; Hao J
    J Immunol; 2016 Nov; 197(10):3831-3840. PubMed ID: 27798164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.